Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
ConclusionAfter 3 years, D-Vd maintained significant benefits in RRMM with a consistent safety profile. D-Vd provided the greatest benefit at first relapse and increased MRD-negativity rates.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Dexamethasone | Jordan Health | Leukemia | Lymphoma | Middle East Health | Myeloma | Revlimid | Study | Velcade